{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05295680",
            "orgStudyIdInfo": {
                "id": "64030"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis.",
            "officialTitle": "A Study of Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis(HAAPS Study).",
            "acronym": "HAAPS",
            "therapeuticArea": [
                "Other"
            ],
            "study": "oral-hymecromone-to-treat-adolescents-and-adults-with-primary-sclerosing-cholangitis"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-10",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-10",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-03-04",
            "studyFirstSubmitQcDate": "2022-03-15",
            "studyFirstPostDateStruct": {
                "date": "2022-03-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-10-04",
            "lastUpdatePostDateStruct": {
                "date": "2023-10-06",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Aparna Goel",
                "investigatorTitle": "Associate Professor of Medicine",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Aparna Goel",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Primary objective: To evaluate the efficacy of hymecromone plus standard of care compared with standard of care alone in the treatment of adolescents and adults with primary sclerosing cholangitis (PSC).\n\nSecondary objectives: To evaluate the change in Alkaline Phosphatase (ALP) from baseline to 6 months post-treatment following treatment with hymecromone plus standard of care compared with standard of care.\n\nTo evaluate changes in biomarkers of PSC disease during hymecromone treatment, namely: (a) fibrotic effect (FibroScan); (b) inflammatory biomarkers (serum Hyaluronan (HA)); and, (c) T-cell count."
        },
        "conditionsModule": {
            "conditions": [
                "Primary Sclerosing Cholangitis"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Hymecromone",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive Hymecromone for six months + Standard Of Care (SOC), and will be followed for an additional nine months.",
                    "interventionNames": [
                        "Drug: Hymecromone"
                    ]
                },
                {
                    "label": "Standard Of Care (SOC)",
                    "type": "NO_INTERVENTION",
                    "description": "Participants will receive Standard Of Care (SOC), and will be followed for 15 months."
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Hymecromone",
                    "description": "Hymecromone 400 mg 3 times daily by mouth.",
                    "armGroupLabels": [
                        "Hymecromone"
                    ],
                    "otherNames": [
                        "Isochol"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in serum gamma-glutamyltransferase (GGT) levels",
                    "timeFrame": "Baseline to Month 6"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in serum Alkaline Phosphatase (ALP) levels",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Change in serum hyaluronan levels",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Change in T-cell count",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Change in fibrotic effect based on FibroScan",
                    "description": "Fibrotic effect is the amount of liver with fatty change",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Change in biliary tree anatomy (e.g. strictures) based on FibroScan",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Change in serum inflammatory cytokine profile",
                    "description": "This outcome measure will assess pro-inflammatory cytokines previously associated with biliary inflammation and other autoimmune diseases including IFNg, IL-6, and TNF.",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Change in lymphocyte immunophenotype",
                    "description": "Single cell analysis technique will be used to assess the lymphocytes (B- and T-cells) present in serum samples, including FoxP3+ regulatory T-cells, a tolerogenic lymphocyte subset with important roles in immune tolerance.",
                    "timeFrame": "Baseline to Month 6"
                },
                {
                    "measure": "Plasma drug levels of 4-MU",
                    "timeFrame": "Single blood draw at baseline, week 2, and months 1, 3, and 6 study visits"
                },
                {
                    "measure": "Plasma drug levels of 4-MUG",
                    "timeFrame": "Single blood draw at baseline, week 2, and months 1, 3, and 6 study visits"
                },
                {
                    "measure": "Plasma drug levels of 4-MUS",
                    "timeFrame": "Single blood draw at baseline, week 2, and months 1, 3, and 6 study visits"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of primary sclerosing cholangitis confirmed by liver biopsy and/or imaging study\n* If history of endoscopically confirmed inflammatory bowel disease, currently stable based on Mayo Score / Disease Activity Index (DAI) for Ulcerative Colitis Score \u2264 1, normal inflammatory markers (ESR, CRP and fecal calprotectin) and stable non-excluded medical therapy for at least 6 months\n\nExclusion Criteria:\n\n* Currently receiving biologic therapies\n* Known allergy to hymecromone\n* Cholangiocarcinoma\n* Pregnancy\n* Serious liver disease",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "14 Years",
            "maximumAge": "75 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Aparna Goel, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                },
                {
                    "name": "Leina Alrabadi, MD",
                    "affiliation": "Stanford University",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford Clinic",
                    "status": "RECRUITING",
                    "city": "Redwood City",
                    "state": "California",
                    "zip": "94063",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Aparna Goel, MD",
                            "role": "CONTACT",
                            "phone": "650-498-7878",
                            "email": "goela21@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.48522,
                        "lon": -122.23635
                    }
                },
                {
                    "facility": "Stanford Clinic",
                    "status": "RECRUITING",
                    "city": "Stanford",
                    "state": "California",
                    "zip": "94305",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Leina Alrabadi, MD",
                            "role": "CONTACT",
                            "phone": "650-721-2250",
                            "email": "alrabadi@stanford.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.42411,
                        "lon": -122.16608
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002761",
                    "term": "Cholangitis"
                },
                {
                    "id": "D000015209",
                    "term": "Cholangitis, Sclerosing"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001649",
                    "term": "Bile Duct Diseases"
                },
                {
                    "id": "D000001660",
                    "term": "Biliary Tract Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6002",
                    "name": "Cholangitis",
                    "asFound": "Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17914",
                    "name": "Cholangitis, Sclerosing",
                    "asFound": "Primary Sclerosing Cholangitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4935",
                    "name": "Bile Duct Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4946",
                    "name": "Biliary Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4712",
                    "name": "Primary Sclerosing Cholangitis",
                    "asFound": "Primary Sclerosing Cholangitis",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}